Posted by Michael Wonder on 29 Jul 2022
Rinvoq (upadacitinib) approved by European Commission as an oral treatment for adults with active non-radiographic axial spondyloarthritis
29 July 2022 - Approval is supported by data from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which Rinvoq delivered meaningful disease control with nearly half of non-radiographic axial spondyloarthritis patients achieving ASAS40 at week 14 (45 percent versus 23 percent; p<0.0001) compared to placebo.
AbbVie today announced that the European Commission has approved Rinvoq (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation, as indicated by elevated C-reactive protein and/or magnetic resonance imaging, who have responded inadequately to non-steroidal anti-inflammatory drugs.
